Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Renova

This article was originally published in The Tan Sheet

Executive Summary

Renova: Johnson & Johnson's Ortho subsidiary to launch Rx skin treatment in February after Dec. 29 approval by FDA. Renova (tretinoin emollient cream .05%) is indicated as an "adjunctive agent for use in the mitigation of fine wrinkles, mottled hyperpigmentation and tactile roughness of facial skin." In clinical trials, most of the skin improvement occurred during the first 24 weeks. "The safety and effectiveness of using Renova daily for greater than 48 weeks have not been established," labeling notes. Renova is contraindicated in pregnant women or those at high risk for pregnancy due to a lack of safety data in those subjects...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084654

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel